TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04476888

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma (CP)
Description: 500 ml of Convalescent plasma in a single dose will be transfused over a period of 1- 2 hours.

Intervention type: OTHER
Group type: OTHER
Intervention: Drugs and supportive care
Description: This will include drugs like steroids, tocilizumab, azithromycin and supportive care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drugs and supportive care
Description: This will include drugs like steroids, tocilizumab, azithromycin and supportive care
Study: NCT04375774

Intervention type: DEVICE
Group type: OTHER
Intervention: FFP2
Description: Face Fit test of the FFP2 with the PortaCount® PRO+ 8038 from TSI

Intervention type: DEVICE
Group type: OTHER
Intervention: Facial mask
Description: Face Fit test of a conventional respirator facial mask with the PortaCount® PRO+ 8038 from TSI

Intervention type: DEVICE
Group type: OTHER
Intervention: MFS
Description: Face fit test of a MFS with the PortaCount® PRO+ 8038 from TSI
Study: NCT05853770

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TGfU volleyball intervention
Description: Duration of intervention: 16 week; Duration of each session: 45 minutes; Frequency: One session per week during the third PE class;~The structure of each TGfU session had three parts:~The introduction part comprised 10 minutes of moderate-intensity warm-up activities; The main part comprised mini-volleyball and small-sided games (25-30 minutes); The last part of the session was the cool-down period (5 min).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular physical education classes
Description: Regular physical education classes following national physical education curriculum for second semester of seventh grade in primary school in Serbia.
Study: NCT01866254

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Injection of 200 mcg of intrathecal morphine
Study: NCT03092232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571
Description: Single ascending dose of PF-06865571 as extemporaneously prepared solution/suspension, once every 2 week in a cross over study: 5 mg, 50 mg, 500 mg, TBD (to be determined)/2000 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571
Description: Single ascending dose of PF-06865571 as extemporaneously prepared solution/suspension, once every 2 week in a cross over study: 15 mg, 150 mg, 1000 mg, TBD/2000 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571
Description: Single repeated (TBD mg) dose as extemporaneously prepared solution/suspension of PF-06865571.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo for PF-06865571 for each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo for PF-06865571 for each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo for PF-06865571 for each cohort.
Study: NCT02953691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galacto-Oligosaccharide
Description: Mixture produced from lactose utilizing the transgalactosidic activity of Bifidobacterium bifidum NCIMB 41171 beta-galactosidase

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin (Placebo)
Description: Maltodextrin is a polysaccharide commonly used as a food additive. It is produced from starch by partial hydrolysis.
Study: NCT00683137

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valdecoxib
Description: valdecoxib 40 mg tablet by mouth followed by a valdecoxib 20 mg tablet by mouth after 1 to 12 hours of the initial dose on Day 1 then a valdecoxib 20 mg tablet by mouth once daily on Days 2 through 5

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valdecoxib
Description: valdecoxib 40 mg tablet by mouth followed by a valdecoxib 20 mg tablet by mouth after 1 to 12 hours of the initial dose on Day 1 then a valdecoxib 20 mg tablet by mouth twice daily on Days 2 through 5

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valdecoxib/placebo
Description: valdecoxib 40 mg tablet by mouth followed by a valdecoxib 20 mg tablet by mouth after 1 to 12 hours of the initial dose on Day 1 then placebo on Days 2 through 5
Study: NCT00976027

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine High Dose
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent inactivated influenza vaccine
Description: 0.5 mL, Intramuscular
Study: NCT01470170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfentanil
Description: Give Alfentanil before TCI Propofol sedative bronchoscope

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfentanil
Description: Give Alfentanil before TCI Propofol sedative bronchoscope

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfentanil
Description: Give Alfentanil before TCI Propofol sedative bronchoscope

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfentanil
Description: Give Alfentanil before TCI Propofol sedative bronchoscope

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: Normal Saline (placebo comparator) was given in equivalent amount of alfentanil dosage in each arm, for double blinded purpose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: Normal Saline (placebo comparator) was given in equivalent amount of alfentanil dosage in each arm, for double blinded purpose.
Study: NCT00133003

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abciximab
Description: 0.25 mg/kg of body weight bolus, followed by a 0.125-microg/kg per minute \[maximum, 10 microg/min\] infusion for 12 hours, plus heparin, 70 U/kg of body weight

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo consist of placebo bolus and infusion of 12 hours (NaCl 0.9%), plus heparin bolus, 140 U/kg of body weight
Study: NCT04122469

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy
Description: The purpose of this study is to evaluate the safety, and efficacy of SBRT in this patient population

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy
Description: The purpose of this study is to evaluate the safety, and efficacy of SBRT in this patient population
Study: NCT01145586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactase Oral Tablets
Description: 3 tablets/day for 42 days Take with breakfast, lunch and dinner

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactase Oral Tablets
Description: 3 tablets/day for 42 days Take with breakfast, lunch and dinner
Study: NCT02423369

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cerebral near infrared spectroscopy
Description: At the start of anesthesia on the patient's forehead two electrodes are attached the for continuous measurement of cerebral near infrared spectroscopy during surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: S-100B protein in serum
Description: 0,5-1 ml of blood from periferal site for determination of serum S-100B concentration.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NSE protein in serum
Description: 0,5-1 ml of blood from periferal site for determination of serum NSE concentration.
Study: NCT00221468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quetiapine
Description: 100mg of quetiapine on day 1 and titrated to a maximum dose of 400mg by day 4, with flexible dosing to 600mg by day 28. The total duration of treatment will be 84 days (12 weeks).
Study: NCT04748367

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Headset
Description: Virtual Reality Headset running SILVER software
Study: NCT01623557

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAd63-MVA CS
Description: 1 dose of ChAd63 CS 5 x 10\^10 vp intramuscularly and 1 dose MVA CS 2 x 10\^8 pfu intramuscularly 8 weeks later.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAd63-MVA ME-TRAP
Description: 1 dose of ChAd63 ME-TRAP 5 x 10\^10 vp intramuscularly and 1 dose MVA ME-TRAP 2 x 10\^8 pfu intramuscularly 8 weeks later.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Controlled Human Malaria Infection Administered by Mosquito Bite
Description: Approximately 3 weeks post MVA dosing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Controlled Human Malaria Infection Administered by Mosquito Bite
Description: Approximately 3 weeks post MVA dosing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Controlled Human Malaria Infection Administered by Mosquito Bite
Description: Approximately 3 weeks post MVA dosing
Study: NCT00771953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apricoxib
Description: Oral apricoxib tablets will be provided as white or off-white film-coated tablets available in 100mg strength to be taken every day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo tablets will be provided as white or off-white film-coated tablets to be taken every day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel or Pemetrexed
Description: Docetaxel 75mg/m2 or Pemetrexed 500mg/m2 given as an IV infusion every 21 days. TheTreating physician will determine chemotherapy drug as per his usual practice.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel or Pemetrexed
Description: Docetaxel 75mg/m2 or Pemetrexed 500mg/m2 given as an IV infusion every 21 days. TheTreating physician will determine chemotherapy drug as per his usual practice.
Study: NCT02933684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seromycin
Description: Seromycin (aka D-cycloserine) is an analogue of D-alanine and a partial agonist at the NMDA receptor, which facilitates the process of fear extinction.
Study: NCT04239625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALK-001
Description: Oral administration of a pill for up to 24 months
Study: NCT03712579

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SFA-Rich Meal
Description: Saturated fatty acid-rich test meal, containing 75g test fat

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MUFA-Rich Meal
Description: Monounsaturated fatty acid-rich test meal, containing 75g test fat
Study: NCT04593069

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neurocognitive assessment
Description: 6 months after admission to the intensive care unit of Ziekenhuis Oost-Limburg, the patients will be tested on cognitive impairment
Study: NCT03993366

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Fiasp+Pramlintide Closed-Loop System
Description: Closed-loop insulin delivery with Fiasp insulin and pramlintide

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fiasp Closed-Loop System
Description: Closed-loop insulin delivery with Fiasp insulin alone
Study: NCT03198208

Intervention type: DRUG
Intervention: Fentanyl dose administration

Intervention type: DRUG
Intervention: Fentanyl dose administration
Study: NCT04428177

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intravascular lithotripsy
Description: Intravascular lithotripsy uses sonic pressure waves to disrupt calcium with minimal impact to soft tissue of coronary vessel

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standart therapy
Description: conventional preparation of calcified lesion: non-compliant, cutting or scoring ballons predilatation or rotational atherectomy
Study: NCT02989519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dydrogesterone
Study: NCT02933684

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy
Description: Allows for delivery of exposure therapy on an iPad. Participants read a speech to a virtual audience. Exposures become increasingly more difficult as the audience becomes more hostile and speeches increase in length and complexity.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Virtual Reality Exposure Therapy
Description: Allows for delivery of exposure therapy on an iPad. Participants read a speech to a virtual audience. Exposures become increasingly more difficult as the audience becomes more hostile and speeches increase in length and complexity.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered in pill form.
Study: NCT04655794

Intervention type: DRUG
Intervention: 3HP
Description: all patients taking 3HP under directly observed preventive therapy (DOPT) program

Intervention type: DRUG
Intervention: 3HP
Description: all patients taking 3HP under directly observed preventive therapy (DOPT) program
Study: NCT01051154

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Docosahexaenoic acid (DHA)
Description: Children will be received either fish oil capsules (DHA group) or placebo capsules (placebo group) which is visually indistinguishable from DHA capsules (softgel). Each child will be receiving 100 mg/kg/day or placebo capsules without docosahexaenoic acid, during the first three months of treatment.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Children will be received either fish oil capsules (DHA group) or placebo capsules (placebo group) which is visually indistinguishable from DHA capsules (softgel). Each child will be receiving 100 mg/kg/day or placebo capsules without docosahexaenoic acid, during the first three months of treatment.
Study: NCT01919281

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: strength training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: interval training
Study: NCT00635258

Intervention type: DRUG
Intervention: triptorelin (Decapeptyl®, Ipsen Pharma, Barcelona, Spain)
Description: 0.1 mg/day triptorelin s.c (Decapeptyl®, Ipsen Pharma, Barcelona, Spain) was started on day 21-24 of the preceding cycle for at least 14 days to produce an agonadal state.

Intervention type: DRUG
Intervention: GnRH antagonist (Orgalutran®)
Description: GnRH antagonist (Orgalutran®; 0,25 mg/d, sc.) commencing on day 1 of the menstrual cycle and maintained until the day of donor's hCG administration.
Study: NCT05423561

Intervention type: PROCEDURE
Group type: OTHER
Intervention: exchange nailing with larger, thicker nail crossing corticalization
Description: exchange nailing with larger, thicker nail crossing corticalization
Study: NCT04986761

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Treatment of implant single crown
Description: Digital or Conventional Workflows for treatment of implant single crown and materials used.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Treatment of implant single crown
Description: Digital or Conventional Workflows for treatment of implant single crown and materials used.
Study: NCT01521312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saxagliptin
Description: 5mg a day for 11-14 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo pill
Description: one tablet a day for 11-14 weeks
Study: NCT00006205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ondansetron + cognitive behavioral therapy
Description: ondansetron (4 mcg/kg b.i.d)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topiramate + cognitive behavioral therapy
Description: topiramate (up to 300 mg/day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + cognitive behavioral therapy
Description: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ondansetron + topiramate + cognitive behavioral therapy
Description: ondansetron (4 mcg/kg b.i.d) + topiramate (up to 300 mg/day)
Study: NCT03061006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran Etexilate
Description: 150 mg BID (CrCL \> 30 mL/min) or 75 mg BID (CrCL \> 15 to 30 mL/min); Assessment of kidney function every 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Dose-adjusted (INR 2.0 - 3.0); Standard warfarin follow-up and education based upon system criteria.
Study: NCT03238690

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Controlled Cardiac Reloading through LVAD Speed Adjustment
Description: LVAD speed is reduced at a fixed rate according to the particular LVAD device model implanted. LVAD speed reduction adjustments will be performed at visits occurring every 2 - 3 weeks, up to a total of 8 visits. Reduction of LVAD speed will continue until the soonest of: minimum operating setting as recommended in the LVAD Operator's manual is reached; the minimum setting tolerated by the subject is reached; the subject completes 8 visits; or until the subject receives a heart transplant.
Study: NCT04079309

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lavender/Orange
Description: A diffuser containing 120 ml water and 0.3 ml lavender oil / 0.3 ml orange oil will be set into the parents' perioperative waiting rooms to mist at least 1 hour before the parent arrive.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lavender/Orange
Description: A diffuser containing 120 ml water and 0.3 ml lavender oil / 0.3 ml orange oil will be set into the parents' perioperative waiting rooms to mist at least 1 hour before the parent arrive.
Study: NCT04551872

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital weight loss intervention
Description: Participants with obesity enter into a proven 6 month weight loss program that utilizes health coaching and goal-setting. It is a remote intervention that is delivered entirely over their phones. Participants will also receive a FitBit and electronic scale.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital weight loss intervention
Description: Participants with obesity enter into a proven 6 month weight loss program that utilizes health coaching and goal-setting. It is a remote intervention that is delivered entirely over their phones. Participants will also receive a FitBit and electronic scale.
Study: NCT00635219

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsules; daily; orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine (Lu AA21004)
Description: 2.5 mg/day; encapsulated tablets; orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine (Lu AA21004)
Description: 5 mg/day; encapsulated tablets; orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine (Lu AA21004)
Description: 10 mg/day; encapsulated tablets; orally

Intervention type: DRUG
Group type: OTHER
Intervention: Duloxetine
Description: 60 mg/day; encapsulated capsules; orally
Study: NCT02133690

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live Attenuated Pentavalent (G1-G2-G3-G4-G9) Human X Bovine Reassortant Rotavirus Vaccine (BRV-PV)
Description: Live Attenuated Pentavalent (G1-G2-G3-G4-G9) Human X Bovine Reassortant Rotavirus Vaccine (BRV-PV), at a dosage of ≥ Log10\^5.6 fluorescent focus units (FFU)/Serotype/Dose in 2.5 ml of buffered diluent

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lyophilized minimal essential medium (MEM) + excipients reconstituted in 2.5 ml of buffered diluents
Study: NCT00984997

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Segmentectomy or lobectomy with en bloc resection of the involved chest.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chest Irradiation
Description: Radiation therapy consists of 60 Gy in 50 fractions for negative margins, or 64.8 Gy in 54 fractions for positive margins, at 1.2 Gy per fraction, 2 fractions per day, 5 days per week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 50 mg/M\^2 given intravenously on days 1 and 8; the cycle will be repeated beginning on day 29.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: given by mouth 30-60 minutes prior to each administration of radiotherapy, on days 1-5 and days 8-12; the cycle will be repeated beginning day 29.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prophylactic Cranial Irradiation
Description: 25 Gy in 10 fractions of 2.5 Gy, 1 fraction per day, will be given at the completion of chest irradiation, and is optional.
Study: NCT01755000

Intervention type: PROCEDURE
Group type: OTHER
Intervention: USCOM scan

Intervention type: PROCEDURE
Group type: OTHER
Intervention: USCOM scan

Intervention type: PROCEDURE
Group type: OTHER
Intervention: USCOM scan

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fluid Bolus
Study: NCT02961738

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Analytic Therapy (CAT)
Description: Cognitive Analytic Therapy (CAT) is a relational, integrative and time-limited psychotherapy. This is a study with two active arms. Therefore in the full CAT arm the participants receive the full therapy, but in the CAT-NR arm participants get CAT with the narrative reformulation aspect removed.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Analytic Therapy (CAT)
Description: Cognitive Analytic Therapy (CAT) is a relational, integrative and time-limited psychotherapy. This is a study with two active arms. Therefore in the full CAT arm the participants receive the full therapy, but in the CAT-NR arm participants get CAT with the narrative reformulation aspect removed.
Study: NCT04640662

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma
Description: Single-injection of 2 ml PRP into the lesion under ultrasound-guided

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet-Rich Plasma
Description: Single-injection of 2 ml PRP into the lesion under ultrasound-guided

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prolotherapy
Description: Single-injection of 2ml dextrose 16.5% into the lesion under ultrasound-guided

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolotherapy
Description: Single-injection of 2ml dextrose 16.5% into the lesion under ultrasound-guided
Study: NCT03023813

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Written material provided.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Written material provided.
Study: NCT03689686

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive Respiratory Support
Description: Physiological crossover prospective study comparing four study trials (20 mins) delivered in computer generated random order:~1. Standard Oxygen therapy with mask~2. HFNC flow 2l/Kg~3. HFNC flow 3l/Kg~4. Helmet CPAP